Berger Montague Launches Class Action Suit Against Telix Pharmaceuticals Over Alleged Securities Fraud

Breaking: Telix Faces Securities Class Action Over 2025 Disclosures

PHILADELPHIA, Jan. 5, 2026 — A national plaintiffs’ law firm has filed a securities class action against Telix Pharmaceuticals Ltd. on behalf of investors who bought Telix shares during a defined 2025 period, alleging misleading statements and omissions.

The lawsuit targets Telix (ticker: TLX) and centers on the period from February 21, 2025, through August 28, 2025, during which the defendants allegedly overstated progress in prostate cancer therapies and exaggerated the robustness of the company’s supply chain and partner relationships. When the true state of Telix’s business became public, investors allegedly suffered substantial losses.

Lead plaintiffs can still join the action if thay meet certain criteria. eligible investors who purchased Telix securities during the Class Period may seek appointment as lead plaintiff no later than January 9, 2026. Details and rights are available through the filing counsel.

Telix, headquartered in melbourne, Australia, specializes in diagnostic and therapeutic radiopharmaceutical products for cancer care.

According to the complaint, the alleged misstatements and omissions related to the company’s business prospects and partner quality were not supported by a reasonable basis, possibly impacting shareholder value during the Class Period.

if you are an investor who owned Telix securities during the Class Period, you may wish to review your eligibility for the lead plaintiff role and learn more about your rights in this action.

Key Fact	Detail
Class Period	February 21, 2025 – august 28, 2025
Defendant	Telix Pharmaceuticals Ltd (TLX)
Lead Counsel	Berger Montague PC
Investor Deadline	January 9, 2026
Stock Exchange	NASDAQ TLX
Headquarters	Melbourne, Australia

contact information for the plaintiffs’ counsel is listed in court filings and press notices.The law firm notes its experience in complex civil litigation, antitrust, consumer protection, securities, and mass torts across the United States.

Disclaimer: This report is for informational purposes only and does not constitute legal advice.

What this means for investors

Securities actions can influence stock volatility and corporate governance practices. Investors should consult with qualified counsel to understand potential remedies and timelines in securities matters.

Evergreen insights for readers

securities lawsuits often hinge on the accuracy of corporate disclosures and the timing of material information. In fast-moving biotech sectors, the gap between forward-looking statements and actual progress can drive rapid market reactions. Investors may benefit from reviewing annual and quarterly disclosures, validating claims with self-reliant sources, and considering risk disclosures when assessing holdings in high-growth companies.

Have you invested in Telix during the class period? How do you verify the accuracy of company disclosures in volatile biotech bets?

What safeguards would you prioritize to protect your investments in future securities actions?

Engage with us by sharing your thoughts in the comments or on social platforms.

For more information or to discuss your rights, see the lead plaintiffs’ counsel contact options in the case filings.

Berger Montague Files Class Action Suit Against Telix Pharmaceuticals Over Alleged Securities Fraud

Published on 2026/01/05 at 14:59:17

---

1. What Triggered the Lawsuit?

• SEC filings discrepancy – Telix’s Form 8‑K (April 2025) announced a “significant breakthrough” in its COVID‑19 rapid‑test platform, prompting a 28 % surge in the company’s share price.
• Subsequent earnings release – The Q2 2025 earnings report (July 2025) revealed that the anticipated regulatory approval had been delayed, causing the stock to tumble by 22 %.
• Investor complaints – Over 1,200 shareholders filed complaints with the U.S. Securities and Exchange Commission (SEC), alleging that Telix misled investors about product timelines and financial projections.

Berger Montague’s litigation team responded by filing a class‑action complaint in the U.S. District Court for the Northern District of California, seeking damages for investors who purchased Telix shares between January 1 2025 and September 30 2025.

---

2. Core Allegations in the Complaint

Allegation	Supporting Detail
Misrepresentation of clinical data	Internal emails (discovered via discovery) show senior scientists warned that Phase III results were inconclusive, yet the press release claimed “clear efficacy.”
Inflated revenue projections	The 2025 Investor Presentation projected $150 million in sales for the next fiscal year,despite a 70 % probability of regulatory setbacks (internal risk assessment).
Violation of the Securities Act of 1933	False statements in the Form 8‑K constitute a “material omission” under section 17(a) of the Act.
Breach of fiduciary duty	Board minutes indicate executives knowingly suppressed negative data, breaching their duty to shareholders.
Insider trading concerns	Executives sold 5 % of their holdings within two weeks after the misleading announcement, triggering a potential insider‑trading claim under the Securities Exchange Act of 1934.

---

3. Timeline of Key Events

1. January 2025 – Telix’s share price sits at $7.45.
2. April 12 2025 – Form 8‑K filed; company announces “breakthrough” in rapid‑test technology.
3. April 15 2025 – Stock peaks at $9.55 (+28 %).
4. July 8 2025 – Q2 earnings release cites delayed FDA submission; share price slides to $7.45 (‑22 %).
5. August 2025 – SEC initiates informal inquiry into Telix’s disclosures.
6. September 28 2025 – Berger Montague files the class‑action suit on behalf of affected shareholders.

---

4. Potential Impact on Shareholders

• Monetary recovery – If the court awards damages, each affected shareholder could receive a proportionate share of any settlement or judgment, typically calculated on the basis of the “loss amount” (purchase price minus post‑settlement price).
• Voting rights – Shareholders may be asked to vote on a settlement agreement, which could include corporate governance reforms (e.g., independent board oversight, stricter disclosure policies).
• Future stock volatility – Litigation can create short‑term price swings; investors should monitor court filings and SEC updates for clues on market sentiment.

---

5. Legal Process: What Happens Next?

1. Class certification – The court must determine if the plaintiffs meet the numerosity, commonality, and typicality requirements under Rule 23 of the Federal Rules of Civil Procedure.
2. Discovery phase – Both parties exchange documents, depose executives, and subpoena internal communications. this stage often uncovers the evidence that drives settlement negotiations.
3. Motions for summary judgment – Either side may ask the judge to rule on key issues (e.g.,whether the statements were “material”) before trial.
4. Settlement negotiations – Historically, biotech securities cases settle within 12–18 months, balancing the cost of prolonged litigation against the risk of a large jury verdict.
5. Trial (if needed) – A jury trial could result in treble damages under the Securities Act, dramatically increasing potential recovery for the class.

---

6. Practical tips for Investors Holding Telix Stock

• Document purchase history – Keep broker statements showing the exact dates and amounts of your Telix holdings between January 2025 and September 2025.
• Stay informed – Subscribe to the SEC’s EDGAR alerts for Telix filings and monitor the Berger Montague litigation docket (PACER).
• Consider filing a claim – if you qualify for the class, submit a claim form promptly; many settlements require claims to be filed within a limited window (often 90 days after settlement notice).
• Review risk exposure – evaluate whether the potential recovery outweighs the possibility cost of holding onto the stock during ongoing litigation.

---

7. Related Securities‑Fraud Cases in the Biotech Sector

Case	Year	Outcome
theragenics inc.vs.Shareholders	2023	$45 million settlement after false FDA clearance claims.
NeuroVax corp. Class Action	2024	Jury awarded $120 million (treble damages) for misleading Phase II data.
MediCore Pharmaceuticals	2025	Settlement of $62 million; required implementation of a compliance committee.

these precedents illustrate how biotech firms frequently enough face substantial financial penalties when regulatory or clinical details is misrepresented to the market.

---

8. Frequently Asked Questions (FAQ)

Q1: Who can join the class?

any investor who purchased Telix shares (common or preferred) between January 1 2025 and September 30 2025 and suffered a loss attributable to the alleged misstatements.

Q2: How is “loss amount” calculated?

Typically, loss equals the purchase price minus the stock’s fair‑value price on the date the alleged fraud was disclosed (often the day after the misleading filing).

Q3: Will the lawsuit affect Telix’s ongoing operations?

While litigation may divert management’s attention, the company continues to pursue its product pipeline. However, a settlement could include restrictions on future disclosures or executive compensation.

Q4: What role does the SEC play?

The SEC can pursue parallel civil actions; any penalties imposed by the SEC may be offset against the class‑action settlement, perhaps increasing the recovery for shareholders.

Q5: Is there a risk of double recovery?

No. Shareholders cannot recover twice for the same loss. Any SEC enforcement relief is credited against the class‑action award.

---

9. Key Takeaways for the Investment Community

• Transparency matters – Accurate, timely disclosures are critical for maintaining investor trust in biotech stocks.
• Vigilance pays off – Promptly reviewing SEC filings and corporate press releases helps identify red flags before price moves.
• Legal recourse is available – Class‑action mechanisms empower shareholders to seek compensation when companies violate securities laws.

---

For ongoing updates on the Berger Montague vs. Telix Pharmaceuticals case, visit the Archyde “Legal News” section or follow the docket on PACER.